Clinical Trials on IPSS Risk Category Intermediate-1 in France
Total 13 results
-
Forma Therapeutics, Inc.RecruitingVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RUnited States, France, Canada, Germany
-
Assistance Publique - Hôpitaux de ParisUnknownInfection | Risk Factors | Myelodysplastic Syndrome (MDS) | IPSS High RiskFrance
-
Centre Francois BaclesseTerminatedProstate Cancer With Intermediate RiskFrance
-
FibroGenAstraZeneca; Astellas Pharma IncTerminatedPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
-
Centre Francois BaclesseFrench cancer Institute INCaRecruitingThyroid Cancer | Intermediate RiskFrance
-
University Hospital, GrenobleRecruitingRadiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation | Intermediate and High-risk Luminal and Triple Negative Breast CancerFrance
-
French Innovative Leukemia OrganisationAbbVie; Janssen-Cilag Ltd.Active, not recruitingIntermediate Risk Chronic Lymphocytic Leukemia | Fit Patients | Risk-Adapted and MRD-Driven StrategyFrance
-
Rennes University HospitalNot yet recruitingHysterectomies for Low- or Intermediate-risk Endometrial CarcinomaFrance
-
Hendrik StreeckJanssen, LPCompletedHIV Infections | Sexual Behavior | HIV-1-infection | Risk ReductionFrance, Hungary, Spain, Poland, Italy
-
University Hospital, BordeauxRecruitingMetastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC ScoreFrance
-
Merck Sharp & Dohme LLCCompletedMyelodysplastic Syndromes | Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Low to Intermediate-1 MDSUnited States, France
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedB-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, Switzerland
-
Karyopharm Therapeutics IncActive, not recruitingAcute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDSUnited States, France, Canada, Spain, China